Alto Neuroscience, Inc. (ANRO)
Market Cap | 298.41M |
Revenue (ttm) | n/a |
Net Income (ttm) | -42.44M |
Shares Out | 26.88M |
EPS (ttm) | -1.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 49,455 |
Open | 11.34 |
Previous Close | 11.40 |
Day's Range | 11.00 - 11.62 |
52-Week Range | 9.40 - 24.00 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 35.00 (+215.32%) |
Earnings Date | Aug 2, 2024 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 215.32% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/f/w/press4-2487828.jpg)
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of a Phase 2 double-blind, placebo-controlled study of its transdermal formulation of A...
![](https://cdn.snapi.dev/images/v1/l/u/press10-2484217.jpg)
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Aw...
![](https://cdn.snapi.dev/images/v1/v/e/conf3-2451446.jpg)
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place J...
![](https://cdn.snapi.dev/images/v1/h/n/press2-2441357.jpg)
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as...
![](https://cdn.snapi.dev/images/v1/q/1/press3-2430738.jpg)
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress...
![](https://cdn.snapi.dev/images/v1/9/x/press18-2421617.jpg)
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced upcoming data presentations that highlight the company's precision psychiatry pipeline and biomarker-b...
![](https://cdn.snapi.dev/images/v1/i/s/press12-2385182.jpg)
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in devel...
![](https://cdn.snapi.dev/images/v1/x/t/press10-2354076.jpg)
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacod...
![](https://cdn.snapi.dev/images/v1/q/t/press8-2336292.jpg)
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress....
![](https://cdn.snapi.dev/images/v1/i/b/press18-2317674.jpg)
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is ...
![](https://cdn.snapi.dev/images/v1/i/z/conf4-2313010.jpg)
Alto Neuroscience to Participate in Upcoming Investor Conferences
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences: Jefferies Bio...
![](https://cdn.snapi.dev/images/v1/r/p/conf17-2295646.jpg)
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at ...
![](https://cdn.snapi.dev/images/v1/r/m/press6-2263071.jpg)
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the closing of its previously announced upsized initial public offering of 9,246,000 shares of common ...
Alto Neuroscience (ANRO) CEO On IPO & Treating Mental Health
Alto Neuroscience (ANRO) went public on the NYSE today. CEO Amit Etkin joins Nicole Petallides to give an overview of the company.
![](https://cdn.snapi.dev/images/v1/i/n/press6-2257069.jpg)
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public off...
![](https://stockanalysis.com/img/news/nyse2.jpg)
CNS disorder biotech Alto Neuroscience files for a $100 million IPO
Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
![](https://stockanalysis.com/img/news/ipo12.jpg)
Alto Neuroscience IPO Registration Document (S-1)
Alto Neuroscience has filed to go public with an IPO on the New York Stock Exchange (NYSE)